Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For…
| Price | $28.32 |
|---|---|
| Market cap | $4.53B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 12-28.72 |
| Beta | 2.1 |
Explore ADPT's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.